促销时间表 Enlivex Therapeutics Ltd.
先进的时间表
简单图表
关于公司
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. The company has a collaboration agreement with BeiGene to evaluate the safety and efficacy of Allocetra in combination with tislelizumab, an anti-PD-1 immune checkpoint inhibitor for the treatment of patients with advanced-stage solid tumors. Enlivex Therapeutics Ltd. 更多详情IPO date | 1995-12-12 |
---|---|
ISIN | IL0011319527 |
Industry | Software |
Sector | Information Technology |
Валюта | usd |
Валюта отчета | usd |
Сайт | https://www.enlivex.com |
Цена ао | 3.91 |
每日价格变化: | -4.8% (1.25) |
---|---|
每周价格变化: | -4.03% (1.24) |
每月价格变化: | +4.39% (1.14) |
3个月内价格变化: | -27.44% (1.64) |
六个月内的价格变化: | -9.98% (1.322) |
每年价格变化: | -55.93% (2.7) |
3年内价格变化: | -81.17% (6.32) |
5年内价格变化: | -84.86% (7.86) |
10年价格变化: | 0% (1.19) |
年初以来价格变化: | -4.8% (1.25) |
|
低估
|
效率
|
|||||||||||||||||||||||||||||||||||||
股息
|
责任
|
成长冲动
|
机构 | 体积 | 分享, % |
---|---|---|
Renaissance Technologies, LLC | 62089 | 0.33 |
Morgan Stanley | 44460 | 0.24 |
Susquehanna International Group, LLP | 27925 | 0.15 |
Edmond De Rothschild Holding S.A. | 13000 | 0.07 |
Geode Capital Management, LLC | 10420 | 0.06 |
Wells Fargo & Company | 9993 | 0.05 |
Citadel Advisors Llc | 7086 | 0.04 |
Citigroup Inc. | 4724 | 0.03 |
UBS Group AG | 3663 | 0.02 |
Steward Partners Investment Advisory, LLC | 3000 | 0.02 |
导师 | 职称 | 支付 | 出生年份 |
---|---|---|---|
Mr. Shai Novik M.B.A. | Executive Chairman | 528k | 1966 (59 年) |
Dr. Oren Hershkovitz Ph.D. | Chief Executive Officer | 273.6k | 1977 (48 年) |
Mr. Veronique Amor-Baroukh | Senior Director of Operations | N/A | |
Ms. Sigal Arad | Director of HR | N/A |
地址: Israel, Ness Ziona, 14 Einstein Street - 在 Google 地图中打开, 打开 Yandex 地图
网站: https://www.enlivex.com
网站: https://www.enlivex.com